SureTrader Advertisement Advertisement Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
ghmm Member Profile
Followed By 42
Posts 5,814
Boards Moderated 0
Alias Born 01/22/06
160x600 placeholder
SABMiller Hit by Weaker Emerging-Market Currencies
More Top Equities Stories Of The Day
Royal Dutch Shell CEO to Call for 'Carbon Pricing'
To Pay for Highways, Lawmakers Propose Taking Money From Banks
SAP Plans New Business Analytics Product--Update
European Court of Justice Declares Transatlantic Data Pact Invalid
Facebook, Eutelsat Team to Provide Internet to Subordinated-Saharan Africa -- Update
FDA Approves Alkermes' Schizophrenia Treatment Aristada
Fuel Prices Fall, but FedEx and UPS Boost Surcharges
Microsoft, Google Agree to Dismiss All Pending Patent Suits
ghmm   Friday, 12/20/13 02:33:34 PM
Re: ghmm post# 171419
Post # of 195669 

Intrexon to Acquire Medistem to Generate Multipotent Cells

Medistem's Stem Cell Technology to be Integrated Into Intrexon's Proprietary Synthetic Biology Platform

I don't follow Intrexon and don't really know what Kirk means by synthetic biology sure seems he has done a wide array of (albeit smaller) deals I don't follow the connection(s) though.

Quote: acquire, for approximately $26 million, San Diego-based Medistem, Inc. (MEDS) a pioneer in the development of Endometrial Regenerative Cells ... Pursuant to the definitive agreement, Medistem stockholders will receive in exchange for each share of Medistem common stock $0.27 in cash and $1.08 worth of Intrexon common stock, based on the 20-day volume-weighted average price of Intrexon's common stock immediately prior to closing.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist